CN Patent

CN118451090A — 一种酰胺类抗病毒化合物

Assigned to Hainan Simcere Pharmaceutical Co ltd · Expires 2024-08-06 · 2y expired

What this patent protects

本发明提供了式(I)所示吡咯烷类化合物及其药学上可接受的盐，以及其作为冠状病毒3CL蛋白酶抑制剂在预防或治疗由冠状病毒感染引起的相关疾病中的用途。

USPTO Abstract

本发明提供了式(I)所示吡咯烷类化合物及其药学上可接受的盐，以及其作为冠状病毒3CL蛋白酶抑制剂在预防或治疗由冠状病毒感染引起的相关疾病中的用途。

Drugs covered by this patent

Paxlovid (Copackaged) (Nirmatrelvir) · Pfizer

Patent Metadata

Patent number: CN118451090A
Jurisdiction: CN
Classification: —
Expires: 2024-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Hainan Simcere Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.